Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Best Practices for Sentinel Events: What Every Healthcare Organization Needs to Know

In any healthcare environment, patient safety is always top of mind. Each staff member is responsible for their own actions. Administrators are too, especially when those actions include reacting to a safety concern raised by an employee. To ensure that healthcare organizations have a high-reliability culture, the Joint Commission Center for Transforming Healthcare published a…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

In any healthcare environment, patient safety is always top of mind. Each staff member is responsible for their own actions. Administrators are too, especially when those actions include reacting to a safety concern raised by an employee. To ensure that healthcare organizations have a high-reliability culture, the Joint Commission Center for Transforming Healthcare published a report, “Sentinel Event Alert 60: Developing a Reporting Culture: Learning from Close Calls and Hazardous Conditions.” 1 The Joint Commission issued this report to encourage a reporting culture where swift action is taken to remedy unsafe conditions.

What Is a Sentinel Event?

The Joint Commission’s mission is “to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value.2 The Joint Commission defines a sentinel event as an unanticipated event in a healthcare setting resulting in death or serious injury, physical or psychological, not related to natural causes or the patient’s illness. The Joint Commission identifies sentinel events in its accreditation policies to assist with root cause analysis and the development of new preventive measures. Accredited organizations are required to define sentinel events for their own care system and implement monitoring procedures and a process for root cause analysis.

Standards Must Be in Place to Respond to a Sentinel Event

Should a sentinel event occur, any accredited healthcare organization must have a process to respond. Causal factors need to be analyzed, focusing on the system holistically. An “action plan” should be put in place for potential improvements to decrease the chance of the event happening again. The Joint Commission encourages organizations to report any sentinel event, but it’s not required. The organization will have to create root cause analysis and an action plan within 45 days of the event. You can also consult with The Joint Commission on initiating the root cause analysis and action plan. If the event was due to a medical device defect, then an organization must report the incident to the Food and Drug Administration within 10 days.

There are benefits to reporting the event that can be of help to other organizations. A reported event is added to the database which other facilities have access to, providing vital information that could help to prevent a similar event from occurring at their organizations.

Sentinel Event Standards

Within the Performance Improvement and Leadership chapters of the accreditation manual, there are standards for the expectations regarding the internal identification and management of sentinel events.

With the organization’s definition of the sentinel event, it must include the specific events that would be reviewed under the Sentinel Event Policy. Following a sentinel event, the organization must begin its investigation by determining root cause analysis, then develop its plan and identify ways to reduce future risk. After the standards are implemented, they are closely monitored to ascertain their viability.

Reporting Is a Key Element of Sentinel Event Management

In order to manage sentinel events, your culture must be one that has adopted reporting. Only with reporting will you be able to truly understand the causes of a particular event and prevent similar events from happening again. The four Es of a Reporting Culture include:3

  1. Establish trust: there can be no culture of reporting without trust; leaders must show their continued commitment to safety and governance should support this as well.
  2. Encourage reporting: this means that reporting is accessible by all staff, easy to use, and delivers data analysis in a timely fashion. Encouragement also means that staff receives feedback so that they know the action is being taken when reports are made. The organization should also define the types of events that should be reported.
  3. Eliminate fear of punishment: ensure that your staff knows that there is no retaliation or punishment for reporting safety concerns. All staff, regardless of position, should be held to the same standards.
  4. Examine errors: refer to the data compiled and use it to identify the highest risk situations and take action. Data is also used to celebrate staff when they are successful. Data helps strengthen the safety program and the culture of reporting.

The Joint Commission also offers resources and support so you can continue to enhance a culture of reporting within your organization.4

https://www.alimed.com/_resources/common/userfiles/file/infographics/AliMed_ReportingCulture-Infographic.pdf

References

  1. https://www.jointcommission.org/
  2. https://www.jointcommission.org
  3. https://www.jointcommission.org/
  4. https://www.jointcommission.org/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

The FDA’s interchangeable biosimilar pathway is moving from a one-off insulin milestone to a repeatable playbook for pharmacy-level substitution, with Wezlana (ustekinumab-auub) approved as interchangeable to Stelara in late 2023 and a first interchangeable biosimilar to golimumab reported in September 2026. Evidence from a JAMA Health Forum economic evaluation cited by Podiatry Today found that insulin glargine interchangeability in November 2021 was followed by an immediate jump of more than 47,000 prescriptions for Semglee and insulin glargine-yfgn, suggesting the designation itself can change dispensing behavior. For hospitals, health systems, and payers, the operational consequence shows up less in the FDA letter and more in formulary design, NDC-level claims logic, pharmacy notification requirements that vary by state, and the inventory and education workflows that make substitution predictable instead of chaotic.

  • 01Interchangeability is a workflow change, not a clinical debate. The systems that decide spend are NDC mapping, e-prescribe defaults, and pharmacy switch rules governed by state law.
  • 02The pipeline is widening beyond diabetes. Wezlana’s interchangeability to Stelara (Healthcare Purchasing News) and a newly reported interchangeable golimumab biosimilar (Journal of Healthcare Management/AJN via Ovid) signal more specialty and infusion-adjacent categories will face pharmacy-level substitution decisions.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512